PubMed · 630199
Prednimustine therapy for advanced prostatic cancer.
Abstract
23 patients with advanced, hormonal-resistant, prostatic cancer were treated with daily oral prednimustine--a combination of prednisolone and chlorambucil. 8 patients (35%) subjectively responded with disappearance of skeletal pain and improvement in appetite, weight and sense of well being. 3 patients had objective evidence of tumour regression. Clinical toxicity was moderate, and only occasional myelosuppression was encountered. The ease of administration and predictable toxicity of prenimustine make it a potentially useful agent, alone or in combination, for advanced prostatic cancer.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
R Catane, J H Kaufman, S Madajewicz, A Mittelman, G P Murphy. 1978. Prednimustine therapy for advanced prostatic cancer.. https://doi.org/10.1111/j.1464-410x.1978.tb02761.x
Cite the original work for its findings. Save a collection to share your selection of sources.